Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

RTTNews | 827日前
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

(RTTNews) - While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.

For fiscal 2023, the company now projects earnings in the range of $7.45 to $8.45 per share and adjusted earnings in the range of $9.90 to $10.90 per share on revenues growth of 2.0 to 4.5 percent, with organic revenues growth of 5.0 to 7.5 percent.

Previously, the company expected earnings in the range of $7.40 to $8.60 per share and adjusted earnings in the range of $9.70 to $10.90 per share on revenues growth of 1.5 to 4.5 percent, with organic revenues growth of 4.5 to 7.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $10.24 per share on revenue growth of 2.80 percent to $4.09 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company reported the net income attributable to common shareholders of $103.13 million or $2.01 per share, higher than $93.02 million or $1.81 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $2.78 per share, compared to $2.75 per share in the year-ago quarter.

Total revenue for the quarter increased 12.6 percent to $1.03 billion from $913.93 million in the same quarter last year. Organic revenue growth was 15.4 percent.

The Street was looking for earnings of $2.59 per share on revenues of $986.35 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 373日前
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1108日前
CAC 40 Up Nearly 1%

CAC 40 Up Nearly 1%

French stocks gaining some ground in positive territory on Friday, continuing their upmove for the fourth consecutive session and expectations the meeting between U.S. President Donald Trump and Russian President Vladimir Putin will help bring about an end to the ongoing war in Ukraine.
RTTNews | 18分前
DAX Up Nearly 0.5%, Hits 5-week High

DAX Up Nearly 0.5%, Hits 5-week High

German stocks are up in positive territory on Friday, rising for the third consecutive session, and the benchmark DAX has hit a more than 5-week high, as some strong earnings updates and hopes about a positive outcome from U.S. President Donald Trump and Russian President Vladimir Putin's meeting help underpin sentiment.
RTTNews | 36分前